Over 25 years of R&D experience in Biotech and Big Pharma, with focus on the development of cancer therapeutics and novel therapeutic platforms, including biotherapeutics and T-cell therapies. Core expertise in oncology and immuno-oncology, spanning from target identification and validation, selection of therapeutic modalities and lead compounds, development of companion diagnostics, translational support for early clinical development and regulatory filings. In depth expertise in preclinical development of therapeutic antibodies, antibody drug conjugates (ADCs), bi-functional compounds (Redirected T-cell Targeting) and conditional approaches (Bispecifics and ADCs), including sdAb and scFv approaches. Experienced with PK-, PD-, toxicology- and bio-distribution studies and methodologies to determine the therapeutic indexes of oncology compounds. Expertise in preclinical and clinical genomics, familiarity with the technical and regulatory requirements of companion diagnostics. Strong track record in leading cross-functional teams, overseeing IND filings of ADCs and Bispecifics and contributions to BLA submissions of therapeutic antibodies (Avastin) and ADCs (Inotuzumab Ozogamicin, Mylotarg). Demonstrated high scientific achievements with over 100 peer-reviewed publications and 20 issued patents. Assumed strategic leadership roles in defining the IO strategy across the Pfizer Oncology Research Organization (ORU). Member of several oncology leadership teams, chairman of multiple joint steering committees and scientific advisory boards and member of board of directors. Proven track record in making initial contacts and to successfully execute external collaborations and licensing deals with academia and corporate partners (Center of Therapeutic Innovation, Seattle Genetics, Ambrx, Cytomx, StemcentRx, Macrogenics, Philogen, IgM. others). Demonstrated strong leadership skills by building cross-functional teams developing industry leading therapeutic platforms and by aligning corporate capabilities to achieve sustainable business results.